Third quarter 2026
Filed Oct 28, 2026Third-quarter net sales declined 45% as Wound sales fell 71%, while Surgical sales increased 9%, gross margin improved sequentially to 80%, and Adjusted EBITDA returned to positive $2,066 (in thousands).
Surgical sales increased 9% and the company returned to positive Adjusted EBITDA, supported by cost actions and sequential gross-margin improvement. However, total net sales declined 45%, Wound sales declined 71%, GAAP net income turned to a loss, and nine-month operating cash flow was negative.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $62.28M | – | decrease of 45% |
| Cost of sales, three months ended September 30, 2026GAAP | $12.58M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $49.70M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 80% | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $58.31M | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $2.80M | – | – |
| Amortization of intangible assets, three months ended September 30, 2026GAAP | $295K | – | – |
| Operating loss, three months ended September 30, 2026GAAP | −$11.70M | – | – |
| Interest income, net, three months ended September 30, 2026GAAP | $776K | – | – |
| Other expense, net, three months ended September 30, 2026GAAP | −$136K | – | – |
| Loss before income tax, three months ended September 30, 2026GAAP | −$11.06M | – | – |
| Income tax benefit, three months ended September 30, 2026GAAP | $2.38M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$8.68M | – | – |
| Basic net loss per common share, three months ended September 30, 2026GAAP | $(0.06) | – | – |
| Diluted net loss per common share, three months ended September 30, 2026GAAP | $(0.06) | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $2.07M | – | – |
| Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP | 3.3 % | – | – |
| Adjusted net loss, three months ended September 30, 2026non-GAAP | −$718K | – | – |
| Adjusted Earnings Per Share, three months ended September 30, 2026non-GAAP | (0.01) | – | – |
| Net cash flows provided by operating activities, three months ended September 30, 2026GAAP | $3.92M | – | – |
| Capital expenditures, including purchases of equipment, three months ended September 30, 2026GAAP | −$166K | – | – |
| Free Cash Flow, three months ended September 30, 2026non-GAAP | $3.75M | – | – |
| Net sales, nine months ended September 30, 2026GAAP | $185.6M | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $135.7M | – | – |
| Selling, general and administrative expenses, nine months ended September 30, 2026GAAP | $171.3M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $9.71M | – | – |
| Operating loss, nine months ended September 30, 2026GAAP | −$46.22M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$34.38M | – | – |
| Diluted net loss per common share, nine months ended September 30, 2026GAAP | $(0.23) | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | −$17.62M | – | – |
| Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP | (9.5) % | – | – |
| Adjusted net loss, nine months ended September 30, 2026non-GAAP | −$14.76M | – | – |
| Adjusted Earnings Per Share, nine months ended September 30, 2026non-GAAP | (0.10) | – | – |
| Net cash flows used in operating activities, nine months ended September 30, 2026GAAP | −$4.22M | – | – |
| Free Cash Flow, nine months ended September 30, 2026non-GAAP | −$5.55M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Surgical, three months ended September 30, 2026Led by sales of AMNIOFIX®, AMNIOEFFECT® and HELIOGEN®; management said Surgical product volume delivered mid-teens growth. | $39.96M | – | increased 9% |
| Wound, three months ended September 30, 2026Negatively impacted by several Medicare reimbursement changes that went into effect on January 1, 2026; sales to Wound Care Centers continued to grow sequentially and unit volume grew 7% sequentially. | $22.32M | – | decrease of 71% |
| Surgical, nine months ended September 30, 2026Product-category net sales reported for the nine months ended September 30, 2026. | $115.6M | – | – |
| Wound, nine months ended September 30, 2026Product-category net sales reported for the nine months ended September 30, 2026. | $70.00M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
2026, fourth quarter 2026 and longer-term outlook
- Revenue2026 net sales of $250 to $260 million
- NoteAdjusted EBITDA for the fourth quarter to be sequentially higher than the third quarter.
- NoteLonger-term annual net sales growth in the low double-digits as a percentage.
- NoteLonger-term adjusted EBITDA margin above 20%.
What drove it
- Surgical sales increased 9% year over year, led by AMNIOFIX®, AMNIOEFFECT® and HELIOGEN® sales.
- Management cited mid-teens Surgical volume growth against a strong prior-year comparison and softer U.S. surgical procedure volumes.
- Cost actions announced in April and lower commissions on lower sales reduced SG&A expense.
- Gross-margin improvement from 69% last quarter to 80% was attributed to cost removal and manufacturing efficiencies.
- The U.S. District Court for the Northern District of Georgia vacated FDA determinations regarding AXIOFILL and remanded both matters to FDA for further consideration consistent with its order.
Concerns
- Wound sales decreased 71% year over year, and management said Medicare reimbursement changes effective January 1, 2026 continued to negatively impact the Wound business.
- Total net sales decreased 45% year over year and GAAP net income changed from $16,748 (in thousands) to a net loss of $(8,683) (in thousands).
- Gross margin was below the prior-year 84%, with the decline attributed primarily to Medicare reimbursement rules affecting Wound product prices and unfavorable product mix.
- SG&A included $6 million of incremental legal and strategic expenses associated with ongoing litigation matters and transaction costs related to the proposed Sanara acquisition.
- The proposed Sanara acquisition remains subject to HSR clearance, and the filing identifies FTC review, financing availability, ticking fees, termination fees, integration risks, and potential unrealized synergies as risks.
What to watch
- Whether fourth-quarter Adjusted EBITDA is sequentially higher than the third quarter, as guided.
- Wound Care Center sales and unit-volume trends as the Wound Care market works through the reimbursement reset.
- Surgical sales and volume growth, including sales of AMNIOFIX®, AMNIOEFFECT® and HELIOGEN®.
- The outcome of FDA's further consideration of AXIOFILL following the court remand.
- Progress toward HSR clearance and completion of the proposed Sanara acquisition.
- Receipt of the four remaining annual $5 million patent-license installments.
Balance sheet and cash flow
- Cash and cash equivalents were $120,791 (in thousands) as of September 30, 2026, compared to $166,121 (in thousands) as of December 31, 2025.
- Net cash increased $2 million compared to the second quarter 2026.
- The Company repaid the remaining $17 million term loan balance and ended the quarter with no debt outstanding.
- Total assets were $264,552 (in thousands) as of September 30, 2026, compared to $342,653 (in thousands) as of December 31, 2025.
- Total liabilities were $53,470 (in thousands) as of September 30, 2026, compared to $86,105 (in thousands) as of December 31, 2025.
- Net cash flows used in investing activities were $(6,470) (in thousands) for the nine months ended September 30, 2026, compared to $(6,551) (in thousands) in the prior-year period.
- Net cash flows used in financing activities were $(34,643) (in thousands) for the nine months ended September 30, 2026, compared to $(4,829) (in thousands) in the prior-year period.
- Net change in cash was $(45,330) (in thousands) for the nine months ended September 30, 2026, compared to $37,667 (in thousands) in the prior-year period.
- A patent licensee will pay MIMEDX a total of $25 million in five equal installments of $5 million; the first installment has been received and four remaining installments will be paid annually on the anniversary of the signing date.
Analysis
MIMEDX reported third-quarter net sales of $62,283 (in thousands), down 45% from $113,725 (in thousands). The result reflected sharply divergent franchise performance. Surgical sales increased 9% to $39,960 (in thousands), led by AMNIOFIX®, AMNIOEFFECT® and HELIOGEN®, while Wound sales decreased 71% to $22,323 (in thousands). Management described Surgical as nearly two-thirds of net sales and cited mid-teens Surgical volume growth despite softer U.S. surgical procedure volumes.
The Wound business remained the principal drag. Management attributed the decline to several Medicare reimbursement changes effective January 1, 2026, which affected Wound product pricing and added pressure to mix. It nevertheless reported sequential sales growth to Wound Care Centers and 7% sequential growth in Wound Care Center unit volume. This developing migration into Wound Care Centers is central to the company's stated view that the market is beginning to adjust.
Profitability improved sequentially but remained substantially below the prior-year period. Gross margin was 80%, up from 69% last quarter, but below 84% a year earlier. MIMEDX attributed the sequential improvement to cost removal and manufacturing efficiencies, whereas the year-over-year decline reflected reimbursement-related Wound pricing pressure and unfavorable product mix. SG&A declined to $58,313 (in thousands) from $69,001 (in thousands), supported by the April cost-reduction initiative and lower commissions, although it included $6 million of incremental legal and strategic expenses.
GAAP net loss was $(8,683) (in thousands), compared with net income of $16,748 (in thousands) a year earlier. Adjusted EBITDA was positive at $2,066 (in thousands), compared with $34,950 (in thousands), and adjusted EBITDA margin was 3.3 % compared with 30.7 %. Quarterly operating cash flow was $3,919 (in thousands) and Free Cash Flow was $3,753 (in thousands), while nine-month operating cash flow and Free Cash Flow were $(4,217) (in thousands) and $(5,551) (in thousands), respectively.
The company ended the quarter with $120,791 (in thousands) of cash and cash equivalents, repaid its remaining $17 million term loan balance, and had no debt outstanding. It now expects 2026 net sales of $250 to $260 million and expects fourth-quarter Adjusted EBITDA to be sequentially higher than the third quarter. Longer term, it continues to target low double-digit annual net sales growth and adjusted EBITDA margin above 20%. The filing also highlighted the AXIOFILL court ruling, a $25 million patent-license agreement, and the unresolved HSR review for the proposed Sanara acquisition.
Management, verbatim
Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.
Joseph H. Capper, MIMEDX Chief Executive Officer
As the Wound Care market works through a sluggish reset, we are beginning to see the anticipated signs of adjustment, including patient migration into Wound Care Centers, where MIMEDX unit volume grew 7% sequentially in the quarter.
Joseph H. Capper, MIMEDX Chief Executive Officer
We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech.
Joseph H. Capper, MIMEDX Chief Executive Officer
Not in the filing
stated, not guessed- No dividend or share-repurchase activity was reported.
- No fourth-quarter 2026 revenue range, gross-margin guidance, operating-expense guidance, or tax-rate guidance was reported.
- No quarterly sequential net-sales comparison was reported for total net sales, Surgical sales, or Wound sales.
- No GAAP operating cash flow, Free Cash Flow, or capital expenditure figures were reported for the immediately preceding quarter.
- No standalone third-quarter Adjusted Gross Profit, Adjusted Gross Margin, or adjusted R&D expense comparison was reported in the primary non-GAAP summary tables.
- The previous outlook covered the full year 2026 and Adjusted EBITDA for the full year only, so there is no quarterly guidance to compare with this third quarter release.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.